APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
96 Views
Wuxi Biologics (2269 HK): 2025 Revenue Beat Guidance; Poised for Accelerated Growth Ahead
Wuxi Biologics surpasses revenue growth guidance, reports record project additions and backlog, and improved margins in 2025. Guidance for 2026...
378 Views
Wuxi Biologics (2269 HK): Expanded Offering and Capacity Drive 1H25 Result; Accelerated Growth Ahead
Per preliminary result, Wuxi Biologics expects 2025 revenue to rise 17% YoY to RMB22B and adjusted net profit to increase 22% YoY to RMB7B, driven...
587 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
StubWorld: WuXi Biologics (2269 HK)'s Double Discounts; Melco (200 HK) Further Out Of Whack
WuXi XDC Cayman (2268 HK)'s Offer for BioDlink International (1875 HK) will add an additional discount layer to WuXi Biologics (2269 HK). Plus...
551 Views